Alkermes (ALKS, Financial) experienced a significant stock movement with a 5.02% increase in its share price, reaching $33.57. The trading volume was 1.375 million shares, with a turnover rate of 0.85% and a price fluctuation of 6.48%.
Recent financial reports show that Alkermes achieved a revenue of $378 million, a net profit of $92.8 million, and earnings per share of $0.57. The company's gross profit was $314 million, leading to a price-to-earnings (P/E) ratio of 16.93.
In terms of institutional ratings, out of nine firms covering the stock, 78% recommend buying, while 22% suggest holding. No firm recommended selling the stock.
Within the pharmaceutical sector, where Alkermes operates, the overall gain was 0.52%. Notable performers in the sector included Sunshine Biopharma Inc C/Wts (To Pur Com), Gilead Sciences, and Cumberland Pharmaceuticals with significant gains. Active stocks included Nature's Sunshine Products, InMed Pharmaceuticals Inc., and Quantum Biopharma Ltd., with turnover rates of 36.23%, 20.79%, and 17.20%, respectively. Stocks with high volatility included Biofrontera Inc C/Wts 27/10/2026, Sunshine Biopharma Inc C/Wts (To Pur Com), and Nature's Sunshine Products.
Alkermes is a fully integrated biotechnology company focused on the research, development, and commercialization of drugs using proprietary technology to address unmet medical needs. The company operates in the U.S., Ireland, and other regions, with the U.S. being its largest revenue source.
